Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1995-9-18
|
| pubmed:abstractText |
Murine reconstitution assays were used to investigate the effects of recombinant human interleukin-7 (rhIL-7) on myeloid and lymphoid precursors and on bone marrow engraftment. Reconstitution with bone marrow from rhIL-7-treated mice results in a 3.4-fold decrease in total colony-forming unit-spleen (CFU-S) activity (day 9) and an 18.1- and 11.9-fold decrease in its ability to generate thymocytes and splenic B lineage cells, respectively. In contrast, after reconstitution with splenocytes from rhIL-7-treated mice, CFU-S activity increased 23.6-fold (day 9) and the thymocyte and splenic B lineage cell regenerative capacity increased by 4.0- and 3.2-fold, respectively. In addition, CD43low+, B220low+ cells that contain pre-pro-B cells and pro-B cells were expanded two- to threefold and Ig mu-, B220+, CD2- and Ig mu-, B220+, CD2+ B lineage cells were expanded approximately 10-fold and 10- to 45-fold (depending on the tissue examined), respectively, after rhIL-7 treatment. Administration of rhIL-7 to irradiated mice transplanted with bone marrow resulted in accelerated T cell and B cell reconstitution by up to 2-4 weeks. Thus, rhIL-7 administration affects the distribution of myeloid and lymphoid precursors. Moreover, rhIL-7 administration accelerates murine bone marrow cell engraftment and therefore may be useful in reducing the engraftment time in bone marrow transplant patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0741-5400
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
58
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
151-8
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7643010-Animals,
pubmed-meshheading:7643010-B-Lymphocyte Subsets,
pubmed-meshheading:7643010-B-Lymphocytes,
pubmed-meshheading:7643010-Bone Marrow Transplantation,
pubmed-meshheading:7643010-Cell Differentiation,
pubmed-meshheading:7643010-Cells, Cultured,
pubmed-meshheading:7643010-Colony-Forming Units Assay,
pubmed-meshheading:7643010-Flow Cytometry,
pubmed-meshheading:7643010-Humans,
pubmed-meshheading:7643010-Interleukin-7,
pubmed-meshheading:7643010-Lymphocyte Transfusion,
pubmed-meshheading:7643010-Lymphocytes,
pubmed-meshheading:7643010-Mice,
pubmed-meshheading:7643010-Mice, Inbred C57BL,
pubmed-meshheading:7643010-Recombinant Proteins,
pubmed-meshheading:7643010-Regeneration,
pubmed-meshheading:7643010-Spleen,
pubmed-meshheading:7643010-Time Factors
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Recombinant human IL-7 administration in mice affects colony-forming units-spleen and lymphoid precursor cell localization and accelerates engraftment of bone marrow transplants.
|
| pubmed:affiliation |
Laboratory of Experimental Immunology, NCI-FCRDC, Frederick, Maryland 21702-1201, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|